Source: YPB
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • YPB (YPB) signs its fourth MotifMicro1 (MM1) paid commercial trial with Manipal Technologies in India
  • Under the paid commercial trial, Manipal will pay for MM1 material to run print trials for a variety of applications for ultra-high-volume clients for 90 days
  • The company considers the agreement to be material as it signifies the first MM1 paid trial in the highly prospective India market with a highly respected and established party
  • YPB shares last traded at 0.10 cents on May 17

Anti-counterfeit and consumer engagement technology group YPB (YPB) has signed its fourth MotifMicro1 (MM1) paid commercial trial with Manipal Technologies in India.

MM1 is YPB’s “revolutionary” forensic anti-counterfeit solution readable by an unmodified smartphone which has the potential to make ultra-secure anti-counterfeit solutions widely available in mass markets globally.

Under the paid commercial trial, Manipal will pay for MM1 material to run print trials for a variety of applications for ultra-high-volume clients for 90 days.

The company considered the agreement to be material as it signifies the first MM1 paid trial in the highly prospective India market with a highly respected and established party.

Executive Chairman John Houston said Manipal is an esteemed and trusted partner to government and major institutions in high population geographies.

“Manipal’s deep expertise in secure solutions again highlights the uniqueness of our technology and the potential leverage of our channel partner strategy to drive rapid market access for MM1,” he said.

Paid commercial trials are a key element of YPB’s MM1 monetisation strategy as this way the company is able to confirm genuine interest from potential partners en route to full commercial contracts.

YPB considered that even though the revenue to the company from the paid trial with Manipal will not in itself be substantial, a follow on agreement would be entered into if Manipal proceeds beyond the trial – which the company said would be more meaningful.

YPB shares last traded at 0.10 cents on May 17.

ypb by the numbers
More From The Market Online

LTR Pharma’s SPONTAN investigation in pulmonary arterial hypertension approved

LTR Pharma has received approval for an investigator-initiated clinical study evaluating SPONTAN in patients with newly…

Wisr delivers record growth and upgrades FY27 guidance

Wisr has reported that its loan book reached $1.2 billion in Q1FY27, increasing 40% to $1,211…

Aquirian receives increased equipment funding facility from NAB to $25M

Aquirian has obtained approval from the National Australia Bank for an increase to the group’s master…
HotCopper Daily Market Trends Graphic

Thursday’s HotCopper trends: AXP Energy, Tambourah Metals, Santos and other daily topics

With more than 600k average monthly users on the HotCopper forums, each and every discussion can…